Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast canceropen access

Authors
Lee, SoohyeonPark, KyungheeKim, Gun MinJung, Kyung HaeKang, Seok YunPark, In HaeKim, Jee HyunAhn, Hee KyungPark, Woong-YangIm, Seock-AhPark, Yeon Hee
Issue Date
4월-2022
Publisher
CHURCHILL LIVINGSTONE
Keywords
Palbociclib; Next-generation sequencing; Progression-free survival; Biomarker
Citation
BREAST, v.62, pp.52 - 60
Indexed
SCIE
SCOPUS
Journal Title
BREAST
Volume
62
Start Page
52
End Page
60
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/143115
DOI
10.1016/j.breast.2022.01.014
ISSN
0960-9776
Abstract
Background: Palbociclib plus endocrine therapy (ET) demonstrated significant progression-free survival (PFS) benefit in Young Pearl, a randomized phase II trial comparing palbociclib + ET versus capecitabine in premenopausal women with hormone receptor positive, HER2 negative metastatic breast cancer (MBC). This exploratory analysis investigated potential biomarkers of palbociclib plus ET on PFS. Patients and methods: Of 178 patients randomized (92 palbociclib plus ET; 86 capecitabine), we performed targeted sequencing (141 patients) and whole transcriptome sequencing (165 patients) using baseline tumor samples to examine genomic alteration in relation to drug response on PFS. Hazard ratios (HRs) were estimated using unstratified Cox proportional hazards models. Results: PIK3CA (41%) and TP53 (33%) mutations and CCND1 copy number variation (29%) were found most frequently in targeted sequencing of 141 patients. ESR1 mutations were found only in 3.5% of patients of this population. Luminal type showed better prognosis in palbociclib + ET arm but no impact on PFS difference in capecitabine arm. High TMB, TP53 mutation, PTEN loss of function mutation and RB1 pathway alteration showed worse prognosis in palbociclib plus ET arm. Patients with BRCA2 pathogenic mutations showed worse prognosis regardless of PAM50 subtypes. AURKA mutation/amplification, BRIP1/MYC/RAD51C amplification were significantly associated to the patients with short PFS <6 month. Conclusion: Of palbociclib plus ET, luminal type showed better prognosis and BRCA2 pathogenic mutation showed worse prognosis regardless luminal/non-luminal type. Further exploration of molecular variables is warranted to determine and validate biomarkers of efficacy and resistance. (C) 2022 The Authors. Published by Elsevier Ltd.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE